Novanta stock sits 19.38 percent below its 52-week high

Published on 10/01/2026 at 15:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novanta stock costs EUR 126.50 on October 1, 2026 versus EUR 125.50. Second-quarter revenue hit USD 265.81 million, 10.30 percent above last year.

NOVT, CA67000B1040, Illustration mit AI erstellt.

Novanta stock stood at USD 142.19 on Nasdaq on September 30, 2026, 19.38 percent below its 52-week high of USD 176.38. In Germany, the shares were trading at EUR 126.50 at Lang & Schwarz on October 1, 2026 at 3:12 p.m. CEST, giving investors two different currency-based reference points for the same company.

Revenue reached USD 265.81 million

Yahoo Finance reported on September 4, 2026 that Novanta's second-quarter revenue reached USD 265.81 million on August 5, 2026, up 10.30 percent from the same period a year earlier. GAAP net income increased to USD 12.50 million from USD 4.50 million, while operating cash flow rose to USD 64.90 million from USD 15.10 million.

The profit and cash figures grew faster than sales, but the quarter also showed a material difference between accounting measures. Adjusted EBITDA rose 16.40 percent to USD 60.70 million, while GAAP diluted earnings per share was USD 0.30 against adjusted diluted earnings per share of USD 0.89, according to Yahoo Finance.

Riverpoint raises the execution bar

Novanta completed its Riverpoint Medical acquisition during the second quarter, and management included the business in its outlook. The company guided for third-quarter GAAP revenue of USD 300 million to USD 304 million, representing growth above 21.00 percent, while full-year adjusted EBITDA guidance called for growth above 24.00 percent, as Yahoo Finance reported.

The acquisition expands Novanta's medical consumables exposure, but the outlook also depends on integration and currency conditions. That combination gives the stock a clear tension: second-quarter operating cash flow reached USD 64.90 million, while the share price remained 19.38 percent below its yearly high.

Nasdaq listing anchors the quote

Novanta describes itself as a supplier of technology solutions for medical, life science and advanced industrial original equipment manufacturers. Its investor-relations page confirms that the common shares are quoted on Nasdaq under the ticker NOVT and that the company is incorporated in New Brunswick, Canada.

The market capitalization was USD 5.1 billion as of September 30, 2026. The primary-exchange 52-week range was USD 98.27 to USD 176.38, placing the September 30 price of USD 142.19 44.70 percent above the low and 19.38 percent below the high.

EUR 126.50 in afternoon trading

Novanta was trading at EUR 126.50 at Lang & Schwarz on October 1, 2026 at 3:12 p.m. CEST, plus 0.80 percent versus the prior close of EUR 125.50 on September 30, 2026. Novanta identifies precision medicine, precision manufacturing, robotics and advanced surgery as core technology areas.